Orbits Oncology
Orbits Oncology converts patient tumor imaging into actionable digital surrogates to help researchers and drug developers make better preclinical decisions. Its automated B2B SaaS platform uses AI and computer vision to analyze live-cell and organoid imaging, performing dye-free cell tracking and subclone analysis to produce reports and visualizations with patient-relevant meaning. The software targets cancer researchers, translational teams and drug developers working on therapy screening, personalized medicine and early-stage oncology programs. By enabling rapid, quantitative tumor phenotyping from microscope images, Orbits Oncology aims to accelerate and de-risk translation from preclinical models to the clinic.
Orbits Oncology
Orbits Oncology converts patient tumor imaging into actionable digital surrogates to help researchers and drug developers make better preclinical decisions. Its automated B2B SaaS platform uses AI and computer vision to analyze live-cell and organoid imaging, performing dye-free cell tracking and subclone analysis to produce reports and visualizations with patient-relevant meaning. The software targets cancer researchers, translational teams and drug developers working on therapy screening, personalized medicine and early-stage oncology programs. By enabling rapid, quantitative tumor phenotyping from microscope images, Orbits Oncology aims to accelerate and de-risk translation from preclinical models to the clinic.
TL;DR
Founded: 2023 (incorporated in USA late 2023)
Headquarters: San Francisco, USA
Product: AI-powered, label-free live-cell and organoid image analysis (B2B SaaS)
Customers / Users: Cancer researchers, translational teams, drug developers
Known investors: AlphaLab; Merck Digital Sciences Studio
Company Overview
Problem Domain
Preclinical oncology research, therapy screening, personalized medicine, and early-stage drug development.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
Pre-seed milestone recorded (Oct 2023) per public profiles
100000 USD
Feb 2025 entry linking AlphaLab to a support program (~$100k) reported in public profiles
Investor Signal
“Early-stage backing from accelerators/support programs (AlphaLab) and participation by Merck Digital Sciences Studio”